HLS Therapeutics Inc. (TSE:HLS) to Post FY2022 Earnings of ($0.70) Per Share, Clarus Securities Forecasts

HLS Therapeutics Inc. (TSE:HLSGet Rating) – Research analysts at Clarus Securities dropped their FY2022 earnings per share estimates for HLS Therapeutics in a report issued on Wednesday, April 27th. Clarus Securities analyst N. Atkinson now anticipates that the company will post earnings per share of ($0.70) for the year, down from their prior estimate of ($0.55). Clarus Securities has a “Buy” rating and a $26.50 price target on the stock. Clarus Securities also issued estimates for HLS Therapeutics’ FY2023 earnings at $0.20 EPS.

HLS Therapeutics (TSE:HLSGet Rating) last released its earnings results on Thursday, March 17th. The company reported C($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.12) by C($0.04). The firm had revenue of C$19.78 million during the quarter, compared to the consensus estimate of C$20.47 million.

Shares of HLS Therapeutics stock opened at C$13.90 on Friday. HLS Therapeutics has a 52-week low of C$13.62 and a 52-week high of C$20.52. The stock’s 50-day simple moving average is C$14.97 and its 200 day simple moving average is C$15.63. The stock has a market capitalization of C$451.07 million and a P/E ratio of -26.94. The company has a debt-to-equity ratio of 60.70, a quick ratio of 1.18 and a current ratio of 1.58.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 15th. Investors of record on Friday, April 29th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date of this dividend is Thursday, April 28th. HLS Therapeutics’s dividend payout ratio is currently -31.06%.

HLS Therapeutics Company Profile (Get Rating)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia.

Recommended Stories

Earnings History and Estimates for HLS Therapeutics (TSE:HLS)

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.